semaglutide phase 2 Higher-Dose Injection Proves Mettle in III Trials 🧪 New Phase 2 Trial:

Contrave combines naltrexone and bupropion to affect appetite and reward pathways, achieving less pronounced weight loss

In the DURATION program for type 2 diabetes: DURATION-1 : Exenatide ER (Bydureon) 2 mg weekly produced 3.7 kg weight loss over 30 weeks DURATION-5 : Bydureon produced 2.3 kg weight loss over 24 weeks Three-year data : Sustained weight reduction of approximately 2.3 kg (5.1 lbs) from baseline Exenatide is not FDA-approved for chronic weight management

However, they emphasize that these drugs have additional health benefits that are often overlooked, particularly in the context of thyroid health

This also explains where Retinol sits in the retinoid family